The strong biomarker-survival correlation and FDA's prior acknowledgment of NfL as a potential surrogate endpoint materially increase the probability of accelerated approval. Monitor FDA filing acceptance and review timelines post NDA submission; clinical hold or CRL risks remain from small sample sizes and post hoc nature of analyses.
Price Chart
Executive Summary
Clene Inc. announced new biomarker analyses linking CNM-Au8 treatment to reduced neurofilament light chain (NfL) levels and improved survival/function in ALS patients. These analyses will be included in an NDA submission for accelerated approval planned for early Q4 2026, addressing FDA feedback from a March 2026 Type C meeting. The filing also includes an updated corporate presentation (Item 7.01).
Key Facts
- CNM-Au8 30 mg participants had a 74% lower risk of death after 12 months vs concurrently randomized controls (p=0.0124) in the HEALEY trial
- NfL decline/stabilization associated with 38% lower risk of death over full follow-up (HR 0.621, 95% CI 0.397-0.972; p=0.037) in HEALEY
- Average survival gain reached nearly six months at four years of follow-up (p=0.012)
- Principal stratum analysis found 41% lower risk of death (HR 0.593, p=0.026) in predicted NfL-responder stratum, preserving randomized comparison
- Observational cohorts (APST, ANSWER ALS) of >2,000 ALS patients showed 10% NfL decline associated with 6-10% lower mortality risk (p<0.0001)
- NDA submission for ALS accelerated approval planned for early Q4 2026
- CNM-Au8 safety profile: >1,280 collective participant-years of treatment, no SAEs related to drug
- Neither HEALEY nor RESCUE-ALS met prespecified primary efficacy endpoint; analyses are post hoc and exploratory
Financial Impact
No financial figures provided in filing; clinical trial data only
Risk Factors
- Analyses are post hoc, exploratory, and from small patient numbers (57 HEALEY, 22 RESCUE-ALS) — not prespecified
- Neither Phase 2 trial met its primary efficacy endpoint
- FDA has not determined NfL is a reasonably likely surrogate endpoint for CNM-Au8 in ALS
- Principal stratum analysis itself is post hoc and not validated prospectively
- Confirmatory Phase 3 trial (RESTORE-ALS) has not yet initiated
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-026653 |
| Document: clnn20260806_8k.htm | 0001437749-26-026653 |
| Document: 0001437749-26-026653-index-headers.html | 0001437749-26-026653 |
| Document: 0001437749-26-026653-index.html | 0001437749-26-026653 |
| Document: 0001437749-26-026653.txt | 0001437749-26-026653 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | 8-K | $3.73 | awaiting T+20 | — | $3.97 (+6.43%) |
Oct 19, 2026 8d ago | 8-K | $3.29 | awaiting T+20 | — | $3.97 (+20.67%) |
Oct 19, 2026 8d ago | Press Release | $3.29 | awaiting T+20 | — | $3.97 (+20.67%) |
Oct 13, 2026 14d ago | SC 13G/A | $3.39 | awaiting T+20 | — | $3.97 (+17.11%) |
Sep 16, 2026 5w ago | 8-K | $4.15 $3.31 | ▲ +20.36% | ▲ +21.57% | $3.97 (+4.34%) |
Sep 16, 2026 5w ago | 424B5 | $3.86 $3.31 | ▲ +14.25% | ▲ +16.31% | $3.97 (−2.85%) |
Aug 14, 2026 10w ago | 8-K | $4.14 $3.28 | ▼ −20.77% | ▼ −18.78% | $3.97 (−4.11%) |
Aug 14, 2026 10w ago | Press Release | $4.14 $3.28 | ▼ −20.77% | ▼ −18.78% | $3.97 (−4.11%) |
Aug 10, 2026 11w ago | 8-K | $5.16 $3.62 | ▼ −29.84% | ▼ −28.93% | $3.97 (−23.06%) |
May 14, 2026 23w ago | 8-K | $7.05 $5.84 | ▼ −17.16% | ▼ −16.30% | $3.97 (−43.69%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers